Parenteral Drugs (India) (NSE:PDPL) Market Cap: ₹101.08 Mil (As of Jun. 26, 2026)


NSE:PDPL Parenteral Drugs (India) Ltd NSE:PDPL
4 GF Score
Price ₹2.90
View Full Analysis

What is Parenteral Drugs (India) Market Cap?

Parenteral Drugs (India) NSE:PDPL 4 Market Cap is ₹101.08 Mil as of Jun. 26, 2026. GuruFocus rates NSE:PDPL with a GF Score™ of 4/100.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Parenteral Drugs (India)'s share price for the quarter that ended in Mar. 2022 was ₹3.6. Parenteral Drugs (India)'s Shares Outstanding (EOP) for the quarter that ended in Mar. 2022 was 29.82 Mil. Therefore, Parenteral Drugs (India)'s market cap for the quarter that ended in Mar. 2022 was ₹107.34 Mil.

Parenteral Drugs (India)'s quarterly market cap increased from Sep. 2021 (₹84.98 Mil) to Dec. 2021 (₹113.30 Mil) but then declined from Dec. 2021 (₹113.30 Mil) to Mar. 2022 (₹107.34 Mil).

Parenteral Drugs (India)'s annual market cap increased from Mar. 2020 (₹77.52 Mil) to Mar. 2021 (₹93.92 Mil) and increased from Mar. 2021 (₹93.92 Mil) to Mar. 2022 (₹107.34 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Parenteral Drugs (India)'s Enterprise Value for Today is ₹1,173.07 Mil.


Parenteral Drugs (India)  (NSE:PDPL) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Parenteral Drugs (India) Market Cap Related Terms


Parenteral Drugs (India) Market Cap Historical Data

* Premium members only.

The historical data trend for Parenteral Drugs (India)'s Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) Market Cap Chart

Parenteral Drugs (India) Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 457.68 251.95 77.52 93.92 107.34

Parenteral Drugs (India) Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 93.92 132.68 84.98 113.30 107.34

NSE:PDPL vs ZTS, CTLT, VTRS: Market Cap Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Parenteral Drugs (India)'s Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parenteral Drugs (India) Market Cap vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parenteral Drugs (India)'s Market Cap distribution charts can be found below:

* The bar in red indicates where Parenteral Drugs (India)'s Market Cap falls into.


NSE:PDPL
4GF Score
Parenteral Drugs (India) Ltd NSE:PDPL
Market Cap is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parenteral Drugs (India) Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Parenteral Drugs (India)'s Market Cap for the fiscal year that ended in Mar. 2022 is calculated as

Market Cap (A: Mar. 2022 )=Share Price (A: Mar. 2022 )*Shares Outstanding (EOP) (A: Mar. 2022 )
=₹3.6*29.816
=₹107.34

Parenteral Drugs (India)'s Market Cap for the quarter that ended in Mar. 2022 is calculated as

Market Cap (Q: Mar. 2022 )=Share Price (Q: Mar. 2022 )*Shares Outstanding (EOP) (Q: Mar. 2022 )
=₹3.6*29.816
=₹107.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of ₹101.08 Mil mean?
Parenteral Drugs (India) (NSE:PDPL) has a Market Cap of ₹101.08 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Parenteral Drugs (India) and its competitors.
Is Parenteral Drugs (India)'s Market Cap too high?
Parenteral Drugs (India)'s current Market Cap is ₹101.08 Mil. Overall, Parenteral Drugs (India) has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Parenteral Drugs (India)'s Market Cap compare to ZTS and CTLT?
Parenteral Drugs (India)'s Market Cap of ₹101.08 Mil can be compared against companies in the Drug Manufacturers industry. The industry median Market Cap is 205.37. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 205.37, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Parenteral Drugs (India) and its competitors. For the Drug Manufacturers industry, the median Market Cap is 205.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parenteral Drugs (India)'s current Market Cap is ₹101.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parenteral Drugs (India) stock overvalued right now?
Parenteral Drugs (India) (NSE:PDPL) has a current Market Cap of ₹101.08 Mil. The current Market Cap is ₹101.08 Mil. Parenteral Drugs (India)'s overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Parenteral Drugs (India) (NSE:PDPL), the current Market Cap is ₹101.08 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parenteral Drugs (India) Business Description

Address Navlakha Crossing, A. B. Road, Shree Ganesh Chambers, Indore, MP, IND, 452001
Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.
4GF Score

Get the complete analysis for NSE:PDPL

Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.90
Price